CE Mark Approval Granted for Cerenovus' Bravo Flow Diverter to Treat Intracranial Aneurysms
August 8, 2018—Cerenovus, part of the Johnson & Johnson Medical Devices Companies, announced it has received European CE Mark approval for the Bravo flow diverter for use in the treatment of intracranial aneurysms. Early evaluations are scheduled to take place across Europe ahead of European commercialization.
The Bravo device is designed to improve clinician ease of use, improve cost effectiveness, and reduce length of procedure. The device is currently not approved for use in the United States.
Professor Patrick Brouwer, MD, commented in the company's announcement, “Flow diverters are now widely used and for many, have become the go to option for the treatment of complex aneurysms. I believe the design of the Bravo flow diverter, particularly the proximal and distal expansion rings, provides a fresh approach to treat aneurysms.” Prof. Brouwer is Senior Consultant Neurointerventionalist at Karolinska University Hospital in Stockholm, Sweden.